<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272883</url>
  </required_header>
  <id_info>
    <org_study_id>03-08-128R</org_study_id>
    <secondary_id>AR44345</secondary_id>
    <secondary_id>NS40828</secondary_id>
    <nct_id>NCT00272883</nct_id>
  </id_info>
  <brief_title>Molecular and Genetic Studies of Congenital Myopathies</brief_title>
  <official_title>Molecular Analysis of Neuromuscular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Congenital Myopathy Research Program at Boston Children's Hospital and Harvard Medical
      School, the researchers are studying the congenital myopathies (neuromuscular diseases
      present from birth), including central core disease, centronuclear/myotubular myopathy,
      congenital fiber type disproportion, multiminicore disease, nemaline myopathy, rigid spine
      muscular dystrophy, SEPN1 and RYR1 myopathy and undefined congenital myopathies. The primary
      goal of the research is to better understand the genes and proteins (gene products) involved
      in muscle functioning and disease. The researchers hope that our studies will allow for
      improved diagnosis and treatment of individuals with congenital myopathies in the future. For
      more information, visit the Laboratory Website at www.childrenshospital.org/research/beggs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Congenital Myopathy Research Program consists of a group of scientists and healthcare
      providers all working to better understand the congenital myopathies. We are taking two
      approaches to reach our research goals. The first involves identifying and describing new
      genes and proteins involved in the skeletal muscles that allow our bodies to move.
      Simultaneously, studies are underway to identify genetic changes (mutations) that cause human
      neuromuscular disease. Thus, our second approach is to identify mutations, learn how they are
      inherited in families, and understand how they lead to weakness in individuals with
      neuromuscular disease. These approaches allow correlation of our basic muscle biology
      findings with our studies on muscle tissue of affected individuals.

      Our research would not be possible without the generous participation of individuals and
      families with congenital myopathies. Participation in our studies is free of charge. Travel
      to Boston is not required, and we welcome the participation of individuals from around the
      world.

      We appreciate the participation of all individuals with a congenital myopathy, as well as
      their first-degree relatives. Participants with a congenital myopathy are asked to donate
      medical records, a blood or saliva sample, and a muscle tissue sample (if available).
      Participating relatives are asked to donate a blood sample. The blood/saliva sample is used
      to acquire DNA (genetic material) which can be used to identify genetic changes and to study
      how a disease is inherited in a family. The medical records are employed to understand a
      participant's symptoms. The muscle tissue is used to better understand the disease at the
      muscular level by studying the gene expression and protein levels in individuals with
      congenital myopathies.

      For more information, visit the Laboratory Website at
      www.childrenshospital.org/research/beggs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">January 2050</completion_date>
  <primary_completion_date type="Anticipated">January 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Neuromuscular Disease Genes</measure>
    <time_frame>The time frame for disease gene discovery is unpredictable and may range from several days to several decades.</time_frame>
    <description>This is an ongoing genetic discovery study aimed at finding and confirming pathogenic mutations in known and new disease genes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of Clinical Features of Congenital Myopathies</measure>
    <time_frame>The time frame for disease classifacation and genotype-phenotype correlation is unpredictable and may range from several days to several decades.</time_frame>
    <description>As known as known and new disease genes are identified the resulting genotypes are correlated with subject phenotypes.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Central Core Disease</condition>
  <condition>Centronuclear Myopathy</condition>
  <condition>Congenital Fiber Type Disproportion</condition>
  <condition>Multiminicore Disease</condition>
  <condition>Myotubular Myopathy</condition>
  <condition>Nemaline Myopathy</condition>
  <condition>Rigid Spine Muscular Dystrophy</condition>
  <condition>Undefined Congenital Myopathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The primary biospecimens retained are blood, saliva and muscle tissue samples. Other
      specimens are retained on a case-by-case basis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with a clinical or suspected diagnosis of a congenital myopathy and their
        family members.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with a clinical or suspected diagnosis of a congenital myopathy and their
             family members

        Exclusion Criteria:

          -  No specific exclusion criteria. Our studies do not include myotonia congenita or
             related conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan H. Beggs, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston/Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casie Genetti, M.S. C.G.C.</last_name>
    <phone>(617) 919-2169</phone>
    <email>cgenetti@enders.tch.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beggs lab</last_name>
    <email>beggslab@enders.tch.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genetics Division, Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casie Genetti, M.S. C.G.C.</last_name>
      <phone>617-919-2169</phone>
      <email>cgenetti@enders.tch.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Alan H. Beggs, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrenshospital.org/research/beggs</url>
    <description>The Beggs lab website</description>
  </link>
  <results_reference>
    <citation>Pierson CR, Tomczak K, Agrawal P, Moghadaszadeh B, Beggs AH. X-linked myotubular and centronuclear myopathies. J Neuropathol Exp Neurol. 2005 Jul;64(7):555-64. Review.</citation>
    <PMID>16042307</PMID>
  </results_reference>
  <results_reference>
    <citation>Agrawal PB, Strickland CD, Midgett C, Morales A, Newburger DE, Poulos MA, Tomczak KK, Ryan MM, Iannaccone ST, Crawford TO, Laing NG, Beggs AH. Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol. 2004 Jul;56(1):86-96.</citation>
    <PMID>15236405</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan MM, Ilkovski B, Strickland CD, Schnell C, Sanoudou D, Midgett C, Houston R, Muirhead D, Dennett X, Shield LK, De Girolami U, Iannaccone ST, Laing NG, North KN, Beggs AH. Clinical course correlates poorly with muscle pathology in nemaline myopathy. Neurology. 2003 Feb 25;60(4):665-73.</citation>
    <PMID>12601110</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan MM, Schnell C, Strickland CD, Shield LK, Morgan G, Iannaccone ST, Laing NG, Beggs AH, North KN. Nemaline myopathy: a clinical study of 143 cases. Ann Neurol. 2001 Sep;50(3):312-20. Review.</citation>
    <PMID>11558787</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanoudou D, Frieden LA, Haslett JN, Kho AT, Greenberg SA, Kohane IS, Kunkel LM, Beggs AH. Molecular classification of nemaline myopathies: &quot;nontyping&quot; specimens exhibit unique patterns of gene expression. Neurobiol Dis. 2004 Apr;15(3):590-600.</citation>
    <PMID>15056467</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanoudou D, Haslett JN, Kho AT, Guo S, Gazda HT, Greenberg SA, Lidov HG, Kohane IS, Kunkel LM, Beggs AH. Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4666-71. Epub 2003 Apr 3.</citation>
    <PMID>12677001</PMID>
  </results_reference>
  <results_reference>
    <citation>Wattanasirichaigoon D, Swoboda KJ, Takada F, Tong HQ, Lip V, Iannaccone ST, Wallgren-Pettersson C, Laing NG, Beggs AH. Mutations of the slow muscle alpha-tropomyosin gene, TPM3, are a rare cause of nemaline myopathy. Neurology. 2002 Aug 27;59(4):613-7.</citation>
    <PMID>12196661</PMID>
  </results_reference>
  <results_reference>
    <citation>Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, Donner K, Jacob RL, Hübner C, Oexle K, Anderson JR, Verity CM, North KN, Iannaccone ST, Müller CR, Nürnberg P, Muntoni F, Sewry C, Hughes I, Sutphen R, Lacson AG, Swoboda KJ, Vigneron J, Wallgren-Pettersson C, Beggs AH, Laing NG. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999 Oct;23(2):208-12.</citation>
    <PMID>10508519</PMID>
  </results_reference>
  <results_reference>
    <citation>North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet. 1999 Apr;21(4):353-4.</citation>
    <PMID>10192379</PMID>
  </results_reference>
  <results_reference>
    <citation>Pelin K, Hilpelä P, Donner K, Sewry C, Akkari PA, Wilton SD, Wattanasirichaigoon D, Bang ML, Centner T, Hanefeld F, Odent S, Fardeau M, Urtizberea JA, Muntoni F, Dubowitz V, Beggs AH, Laing NG, Labeit S, de la Chapelle A, Wallgren-Pettersson C. Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2305-10.</citation>
    <PMID>10051637</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottenheijm CA, Lawlor MW, Stienen GJ, Granzier H, Beggs AH. Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathy. Hum Mol Genet. 2011 May 15;20(10):2015-25. doi: 10.1093/hmg/ddr084. Epub 2011 Feb 28.</citation>
    <PMID>21357678</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawlor MW, Dechene ET, Roumm E, Geggel AS, Moghadaszadeh B, Beggs AH. Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber hypotrophy in congenital fiber type disproportion. Hum Mutat. 2010 Feb;31(2):176-83. doi: 10.1002/humu.21157.</citation>
    <PMID>19953533</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottenheijm CA, Hooijman P, DeChene ET, Stienen GJ, Beggs AH, Granzier H. Altered myofilament function depresses force generation in patients with nebulin-based nemaline myopathy (NEM2). J Struct Biol. 2010 May;170(2):334-43. doi: 10.1016/j.jsb.2009.11.013. Epub 2009 Nov 26.</citation>
    <PMID>19944167</PMID>
  </results_reference>
  <results_reference>
    <citation>Laing NG, Dye DE, Wallgren-Pettersson C, Richard G, Monnier N, Lillis S, Winder TL, Lochmüller H, Graziano C, Mitrani-Rosenbaum S, Twomey D, Sparrow JC, Beggs AH, Nowak KJ. Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1). Hum Mutat. 2009 Sep;30(9):1267-77. doi: 10.1002/humu.21059.</citation>
    <PMID>19562689</PMID>
  </results_reference>
  <results_reference>
    <citation>Ottenheijm CA, Witt CC, Stienen GJ, Labeit S, Beggs AH, Granzier H. Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency. Hum Mol Genet. 2009 Jul 1;18(13):2359-69. doi: 10.1093/hmg/ddp168. Epub 2009 Apr 4.</citation>
    <PMID>19346529</PMID>
  </results_reference>
  <results_reference>
    <citation>Lehtokari VL, Greenleaf RS, DeChene ET, Kellinsalmi M, Pelin K, Laing NG, Beggs AH, Wallgren-Pettersson C. The exon 55 deletion in the nebulin gene--one single founder mutation with world-wide occurrence. Neuromuscul Disord. 2009 Mar;19(3):179-81. doi: 10.1016/j.nmd.2008.12.001. Epub 2009 Feb 15.</citation>
    <PMID>19232495</PMID>
  </results_reference>
  <results_reference>
    <citation>Pierson CR, Agrawal PB, Blasko J, Beggs AH. Myofiber size correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy. Neuromuscul Disord. 2007 Jul;17(7):562-8. Epub 2007 May 29. Erratum in: Neuromuscul Disord. 2008 Jun;18(6):519.</citation>
    <PMID>17537630</PMID>
  </results_reference>
  <results_reference>
    <citation>Agrawal PB, Greenleaf RS, Tomczak KK, Lehtokari VL, Wallgren-Pettersson C, Wallefeld W, Laing NG, Darras BT, Maciver SK, Dormitzer PR, Beggs AH. Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. Am J Hum Genet. 2007 Jan;80(1):162-7. Epub 2006 Nov 14.</citation>
    <PMID>17160903</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2006</study_first_submitted>
  <study_first_submitted_qc>January 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Alan H. Beggs</investigator_full_name>
    <investigator_title>Sir Edwin &amp; Lady Manton Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>central core</keyword>
  <keyword>centronuclear</keyword>
  <keyword>multiminicore</keyword>
  <keyword>multicore</keyword>
  <keyword>minicore</keyword>
  <keyword>congenital fiber type disproportion</keyword>
  <keyword>myotubular</keyword>
  <keyword>nemaline</keyword>
  <keyword>congenital myopathy</keyword>
  <keyword>neuromuscular</keyword>
  <keyword>rigid spine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
    <mesh_term>Myopathies, Nemaline</mesh_term>
    <mesh_term>Myopathy, Central Core</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

